Gene Therapy Analytics CDMO Services

Gene Therapy Analytics Services

Sophia provides gene therapy analytics CDMO services for sponsors developing AAV vectors, lentiviral vectors, adenoviral vectors, HSV vectors, plasmid DNA starting materials, genome-editing products, ex vivo cell therapy vectors, in vivo gene therapies, viral vector vaccines, and other advanced genetic medicines.

That is the central problem. Gene therapy products are not defined by one number. A high vector genome titre does not prove infectivity. Infectivity does not prove potency.

Potency does not prove genome integrity. Genome integrity does not prove low residual DNA. Low residual DNA does not prove the absence of replication-competent virus. A visually clean preparation can still contain empty capsids, truncated genomes, aggregates, host-cell proteins, residual nucleases, plasmid DNA, or process-related contaminants.

Gene therapy analytics is where the product stops being an idea and becomes measurable. A vector may carry the right gene, use the right capsid, show strong expression in a research model, and still remain unsuitable for clinical development if its identity, titre, purity, potency, genome integrity, infectivity, residual impurities, replication risk, stability, and batch consistency are not understood.

Sophia’s gene Therapy analytics CDMO services support analytical method development, qualification, validation strategy, vector identity, physical and functional titre, genome integrity, capsid characterisation, empty/full analysis, aggregation, infectivity, potency, residual host-cell DNA, residual plasmid DNA, host-cell proteins, nuclease residues, endotoxin, sterility, mycoplasma, replication-competent virus strategy, stability, comparability, release specifications, and CMC documentation.

The objective is not to generate a pile of assay reports. It is to build an analytical system that explains the product.

Why Gene Therapy Analytics Matters

Gene therapy products are biologically powerful and analytically difficult. They combine nucleic acid, protein, viral structure, cellular interaction, manufacturing history, and biological function in one product. A vector has to carry the intended sequence, survive purification, enter the correct cell, release its genome, express the intended product, and remain within acceptable safety and impurity limits.

Each of those steps creates a different analytical question.

The nucleic acid component raises questions about identity, sequence fidelity, genome size, integrity, truncation, recombination, residual plasmid, residual host DNA, and packaged non-target DNA. The capsid or viral particle raises questions about identity, composition, aggregation, empty particles, full particles, partially filled particles, stability, and surface structure. The biological function raises questions about infectivity, transduction, expression, editing, integration, or therapeutic activity.

The product also carries a manufacturing fingerprint. The cell line, plasmids, helper system, media, harvest method, nuclease treatment, clarification, chromatography, filtration, concentration, and formulation can all leave measurable consequences.

A strong gene therapy analytics CDMO services programme therefore does more than confirm that a batch exists. It shows whether the batch is the intended product, whether it performs, whether it is sufficiently controlled, and whether it is comparable with previous and future batches.

History of Gene Therapy Analytics

Gene therapy began with a biological ambition: repair disease at the level of genetic instruction. The first programmes were built around a powerful intuition. If disease came from a missing or defective gene, perhaps a working gene could be delivered. The earliest development culture naturally focused on whether the vector could enter cells and produce the desired biological effect.

Analytics initially followed the biology. Researchers measured expression, transduction, or a visible phenotypic change. If the vector worked in cells or animals, the programme moved. That was understandable. The field was proving that gene transfer was possible at all.

But therapeutic development has a way of forcing every hidden question into the open.

As programmes entered clinical development, it became clear that “the vector works” was not a sufficient product definition. How many particles were present? How many carried the intended genome? How many were infectious? Were genomes intact? Were particles aggregated? Were empty capsids present? Did the preparation contain residual host-cell DNA, plasmid DNA, proteins, nuclease, helper-virus components, or replication-competent material? Did the potency assay reflect the intended mechanism? Did the product remain stable after freezing, thawing, shipping, dilution, and administration?

The analytical field expanded because the product demanded it.

AAV brought particular complexity. It could be measured by vector genome titre, capsid titre, infectious titre, transducing units, expression, or functional potency, but these measurements did not necessarily agree. Two batches with similar vector genome titre could behave differently. A preparation could contain substantial empty capsid burden. Packaged genomes could be truncated or rearranged. Capsids could aggregate or degrade. The ratio between physical particles and functional particles became an important part of understanding product quality.

Lentiviral vector development added another analytical architecture. Functional transduction, particle-associated markers, reverse transcriptase activity, residual plasmid DNA, host-cell impurities, envelope integrity, vector copy number, and replication-competent lentivirus risk all mattered. For ex vivo cell therapy, the vector was only one part of the final product, but its quality directly influenced cell manufacturing, transduction efficiency, copy number, potency, and safety.

Adenoviral, HSV, and other viral systems brought their own questions. Larger genomes, different particle structures, helper systems, replication competence, infectivity, capsid composition, and product-specific impurities required tailored assays.

The history of gene therapy analytics is therefore the history of the field learning to see its own products. Early gene therapy asked whether genetic delivery was possible. Modern gene therapy asks what was delivered, how much was delivered, how intact it was, how active it was, what else came with it, and whether the next batch will behave the same way.

In that sense, analytics became the field’s memory. Without analytics, every batch is a new anecdote. With analytics, a platform becomes reproducible.

What Gene Therapy Analytics Must Explain

A complete analytical strategy should answer several distinct product questions.

Identity: Is this the intended vector, capsid, genome, construct, and product?
Quantity: How many genomes, particles, infectious units, or functional units are present?
Purity: What residual host, plasmid, process, or product-related impurities remain?
Function: Can the product enter target cells and produce the intended biological effect?
Consistency: Does the batch remain comparable across process changes, scales, sites, and time?

These questions are related but not interchangeable. A single assay cannot carry the entire control strategy.

Gene Therapy Product Types Supported

Sophia supports gene therapy Analytics Services across viral, non-viral, in vivo, ex vivo, and genome-editing products.

AAV programmes may include different capsids, natural or engineered serotypes, tissue-targeted vectors, self-complementary vectors, single-stranded vectors, dual-vector systems, liver-directed products, neuromuscular products, ocular products, CNS programmes, cardiovascular programmes, and rare disease therapies.

Lentiviral vector programmes may include ex vivo cell therapy vectors, CAR-T and CAR-NK vectors, haematopoietic stem cell products, immune-cell engineering, stable gene addition, research vectors, and clinical manufacturing vectors.

Adenoviral and HSV programmes may include vaccines, oncolytic products, gene delivery systems, immune-stimulating vectors, and larger-cargo programmes.

Non-viral genetic medicine programmes may include plasmid DNA, minicircle DNA, transposon systems, CRISPR components, donor templates, editing reagents, RNP-associated materials, and nucleic acid delivery systems.

Each modality needs a tailored assay architecture. The analytical plan should follow the product mechanism and manufacturing process rather than forcing every modality through the same generic panel.

Vector and Genome Identity

Sophia supports identity testing for vector capsid, envelope, genome, transgene, promoter, regulatory elements, plasmid inputs, and final product.

Identity methods may include PCR, qPCR, ddPCR, sequencing, restriction mapping, capillary electrophoresis, peptide mapping, LC-MS, immunoassays, serotype-specific assays, Western blot, and product-specific molecular methods.

Genome identity is more than confirming one short sequence. The construct may contain promoter, enhancer, coding sequence, intron, untranslated regions, polyadenylation signal, regulatory elements, and inverted terminal repeats. A short PCR assay may confirm one region while missing truncation elsewhere.

For AAV, intact genome strategy may require multiple amplicons, sequencing, electrophoretic methods, analytical ultracentrifugation-adjacent data, or long-read approaches during development. For lentivirus, vector identity may include transfer vector sequence, envelope, packaging components, and functional transduction. For editing products, identity may include guide sequence, nuclease identity, donor template, and editing outcome.

The analytical question is not merely “did we detect the transgene?” It is “is the packaged or delivered genetic material the intended product?”

Physical Titre and Particle Quantification

Physical titre measures the amount of vector or particle present, but the meaning depends on modality.

For AAV, vector genome titre may be measured by qPCR or ddPCR. Capsid particle concentration may be assessed through immunoassays, optical methods, analytical ultracentrifugation-related approaches, mass photometry during development, or other particle methods. For lentiviral vectors, physical measures may include p24, reverse transcriptase activity, particle-associated RNA, or nanoparticle-related methods.

Physical titre is useful, but it is not potency. A particle can exist without being functional. An AAV capsid can be empty. A lentiviral particle can contain defective genome or lose envelope function. A vector genome result can include damaged or non-functional material depending on method design and sample treatment.

Sophia supports titre methods designed around assay purpose, including development, in-process testing, characterisation, release, and comparability.

A number without a clear biological meaning is only a number.

Functional and Infectious Titre

Functional titre measures the ability of a vector to enter cells and perform a defined function. Sophia supports assay strategy for transducing units, infectious units, gene expression, reporter systems, vector copy number, cell-based transduction, protein expression, enzyme activity, and product-specific functional readouts.

For lentiviral vectors, functional titre may be measured by transduction of a suitable cell line followed by flow cytometry, qPCR, ddPCR, reporter expression, or target gene detection. For AAV, infectivity or transduction assays may involve permissive cells, helper conditions, reporter systems, transgene expression, or functional protein production.

Functional assays are often variable because they depend on cells. Cell passage, receptor expression, confluence, media, incubation time, vector dilution, assay endpoint, and operator technique can all influence results. The assay must be controlled carefully enough to provide useful information.

The ratio of physical to functional titre can also reveal process quality. A rising particle-to-functional-unit ratio may indicate empty particles, damaged particles, poor genome packaging, weak infectivity, or process stress.

The batch should not only contain vectors. It should contain vectors capable of doing the intended work.

AAV Empty, Full, and Partial Capsid Analysis

AAV products may contain empty capsids, full capsids, partially packaged capsids, overfilled species, aggregates, and other particle variants. Sophia supports empty/full analysis and capsid distribution strategy across development, process optimisation, comparability, and release planning.

Methods may include analytical ultracentrifugation, charge-detection mass spectrometry interface, mass photometry during development, cryo-electron microscopy in specialised characterisation, ion-exchange chromatography, capillary isoelectric focusing, optical spectroscopy, and orthogonal particle methods.

Empty capsids may influence dose, immunogenicity, process yield, and interpretation of vector genome titre. Partial particles may contain truncated genomes or non-target DNA. Full-capsid percentage alone does not prove genome integrity. A “full” particle may still contain an incorrect or incomplete genome.

This is why empty/full analysis should be connected with genome integrity and potency. The capsid can be physically full while the product remains biologically wrong.

Genome Integrity and Packaged DNA Characterisation

Sophia supports genome integrity testing for full-length transgene confirmation, truncation, rearrangement, partial packaging, backbone packaging, helper-sequence packaging, host-cell DNA packaging, and unintended nucleic acid content.

Methods may include qPCR or ddPCR across multiple genome regions, capillary electrophoresis, next-generation sequencing, long-read sequencing during development, Southern blot-style characterisation where justified, restriction analysis, nuclease protection studies, and product-specific molecular methods.

Genome integrity matters because gene therapy vectors can package incomplete or unintended sequences. A titre assay aimed at one small region can overestimate usable genome if other regions are missing. Manufacturing changes may alter packaging quality without dramatically changing total vector genome titre.

For editing products, genome characterisation may also include on-target editing, insertion-deletion profiles, donor integration, off-target assessment strategy, and vector-derived sequence persistence.

A vector is not defined by how much DNA it contains. It is defined by whether it contains the right DNA in the right form.

Capsid, Envelope, and Structural Characterisation

Sophia supports structural characterisation of AAV capsids, lentiviral envelopes, adenoviral particles, HSV particles, and engineered vector components.

Relevant testing may include capsid protein identity, VP protein ratio, peptide mapping, LC-MS, intact protein analysis, Western blot, immunoassay, charge variants, particle size, aggregation, morphology during development, thermal stability, and surface marker characterisation.

For AAV, capsid composition and VP ratio may influence assembly, infectivity, tissue targeting, and stability. For lentivirus, envelope integrity is central to functional transduction. For engineered capsids or pseudotyped vectors, structural identity should be connected to biological performance.

Process conditions can affect vector structure. Shear, freeze-thaw, pH, salt, concentration, filtration, and formulation may alter particle integrity or aggregation. Structural analytics help show whether the vector survived manufacturing.

Potency Assay Development

Potency is one of the most important and difficult areas in gene therapy analytics. Sophia supports potency assay development for transgene expression, enzyme activity, receptor function, protein secretion, gene editing, cell phenotype, functional correction, immune activity, and other product-specific mechanisms.

A potency assay should reflect the intended biological activity of the product. For an enzyme replacement gene therapy, potency may include transduction and functional enzyme activity. For a secreted protein product, expression and biological activity may both matter. For an editing product, potency may include editing efficiency and functional outcome. For an oncolytic virus, infectivity and tumour-cell killing may be relevant.

Potency assays often evolve across development. An early assay may use a reporter or surrogate cell line. A later assay may need stronger connection to clinical mechanism. The final assay should be sufficiently controlled for the development stage and useful for release, stability, or comparability.

The strongest potency strategy often uses a matrix of methods during development, then selects a practical control assay supported by deeper characterisation.

Residual Host-Cell and Process Impurities

Gene therapy products may contain host-cell DNA, host-cell proteins, residual plasmid DNA, residual helper DNA, nucleases, benzonase-like enzymes, chromatography ligands, detergents, antibiotics, serum components, media components, transfection reagents, and other process-related impurities.

Sophia supports impurity testing and control strategy for:

Residual host-cell DNA
Residual plasmid or helper DNA
Host-cell proteins
Residual nuclease
Residual transfection reagent
Residual antibiotics
Residual solvents or detergents
Process resin or ligand leachables
Endotoxin
Bioburden, sterility, and mycoplasma

The correct panel depends on the production system. HEK293 transfection-based AAV has a different impurity profile from baculovirus-insect-cell AAV. Producer-cell lentivirus has different residual risks from transiently transfected lentivirus. Adenovirus, HSV, and plasmid DNA each require their own process-linked strategy.

Impurity testing should follow the process map. Generic testing panels can miss the impurities most likely to matter.

Replication-Competent Virus Strategy

Replication-competent virus testing is a critical safety area for replication-defective viral vector products. Sophia supports assay strategy for replication-competent lentivirus, replication-competent adenovirus, helper-virus contamination, adventitious virus, and product-specific viral safety concerns.

The assay design depends on vector system, cell substrate, helper components, production method, and development stage. Testing may include amplification culture, molecular detection, indicator cell systems, infectivity endpoints, and product-specific confirmatory methods.

Replication-competent virus assays can be lengthy, biologically variable, and technically demanding. They need appropriate controls, sensitivity, sample volume, interference testing, and defined interpretation.

The analytical system must also distinguish theoretical risk from demonstrated process control. Good vector design, raw material control, cell banking, plasmid design, and production strategy reduce risk. Testing confirms that the risk remains controlled.

Sterility, Mycoplasma, Endotoxin, and Adventitious Agents

Gene therapy products may be administered intravenously, intrathecally, intraocularly, intramuscularly, locally, or through ex vivo cell manufacturing. Microbial and adventitious-agent control is therefore essential.

Sophia supports sterility strategy, rapid microbiological methods interface, mycoplasma testing, endotoxin testing, bioburden, viral safety testing, adventitious-agent strategy, raw material review, and phase-appropriate release planning.

Short shelf life or frozen product handling may affect release timing. Some tests may not be complete before administration in certain development settings, which increases the importance of process control, aseptic manufacturing, environmental monitoring, and justified release procedures.

Microbial quality is not separate from gene therapy quality. It is part of the product’s basic fitness for use.

Stability-Indicating Analytics

Sophia supports stability-indicating methods for vector titre, potency, aggregation, genome integrity, capsid integrity, infectivity, pH, appearance, osmolality, purity, and product-specific degradation.

Gene therapy products may be sensitive to freezing, thawing, agitation, light, temperature, dilution, adsorption, concentration, and container interaction. AAV may aggregate or lose infectivity. Lentivirus may lose envelope function. Potency may decline before physical titre changes. Genome integrity may remain measurable even after functional activity falls.

Stability programmes may include long-term storage, accelerated conditions, freeze-thaw, shipping simulation, agitation, thawed hold time, administration-device compatibility, dilution stability, and in-use stability.

Comparability and Process Change

Gene therapy programmes change. Scale increases. Manufacturing sites change. plasmid suppliers change. Cell banks change. chromatography steps change. Formulation changes. Analytical methods improve. Sophia supports comparability strategy across these transitions.

Comparability may include side-by-side testing of identity, physical titre, functional titre, potency, empty/full ratio, genome integrity, capsid composition, aggregation, impurities, stability, and process performance.

The analytical burden depends on the significance of the change. A small buffer adjustment is not equivalent to a new production platform. A new capsid, producer cell, plasmid configuration, purification method, or formulation can alter critical quality attributes.

Comparability works best when analytical understanding is built before the change. Trying to invent the product definition after a major process transition is expensive and weak.

Phase-Appropriate Method Development

Analytical methods should mature with the programme. Early development needs speed and understanding. Clinical development needs greater control. Commercial readiness requires robust validation, transferability, lifecycle management, and sustained performance.

Sophia supports method progression through:

Feasibility and assay selection
Method development
Qualification
Validation strategy
Transfer to quality control
Bridging and comparability
Method lifecycle management

Not every early assay needs commercial validation. But every critical assay should have a clear path towards greater control. Phase-appropriate does not mean vague. It means the level of control matches the development stage and product risk.

GMP, CMC, and Regulatory Documentation

Sophia supports GMP/GMP-like and CMC documentation for gene therapy analytics CDMO services, including analytical development reports, method qualification, validation protocols, validation reports, method transfer, specifications, sampling plans, stability protocols, comparability plans, reference standard strategy, certificate of analysis, out-of-specification investigation, deviation handling, change control, and data review.

A coherent CMC analytical package should connect critical quality attributes to process understanding and product function. It should explain which methods are used, why they are suitable, how they are controlled, and what acceptance criteria mean.

Reference standards are also important. Gene therapy programmes may require internal standards, assay controls, cell banks, plasmid standards, vector standards, potency controls, and stability-indicating comparators. These materials need qualification, storage, and lifecycle planning.

The analytical dossier should make the vector understandable to someone who did not manufacture it.

Why Sophia for Gene Therapy?

Sophia delivers gene therapy analytics as a complete European platform built for programmes that cannot afford incomplete answers. We support advanced genetic medicine through molecular analytics, full viral vector characterisation, cell-based potency, particle and structural testing, impurity profiling, stability-indicating methods, comparability, and rigorous European quality execution. The work is designed so that every data package does more than report a number—it explains the vector’s identity, integrity, and functional behaviour under real process and product conditions.

We operate across AAV, lentiviral, adenoviral, HSV, and non-viral systems with equal seriousness. Vector and genome identity confirmation, qPCR and ddPCR titre strategies, physical, infectious and functional titre determination, AAV empty/full and particle distribution analysis, genome integrity and packaged DNA characterisation, capsid, envelope and structural analytics, potency assay development, residual host-cell DNA, plasmid DNA, protein and nuclease testing, replication-competent virus strategies, sterility, mycoplasma, endotoxin and adventitious-agent testing, stability-indicating assays, comparability and process-change support, method qualification, validation and transfer, and GMP or GMP-like documentation are all executed under one coherent analytical logic. Spain- and Switzerland-linked laboratory execution provides the European quality and regulatory alignment many sponsors require.

The platform is deliberately built for sponsors who need the analytics to reveal how the vector actually behaves—not merely to measure isolated attributes. Process changes, formulation shifts, and scale transitions are interrogated with the same depth as routine release testing. Residual impurities are tracked at the sensitivity levels that matter for clinical and commercial risk. Potency is developed as a living biological response rather than a single endpoint. The result is data that stands up to regulatory scrutiny while remaining useful for process understanding and decision-making.

Sophia accepts both high-volume commercial analytics and the specialised, low-volume, or technically demanding work that most facilities decline. Rare vector serotypes, complex multi-component non-viral systems, highly sensitive residual testing, and custom potency formats for novel payloads sit alongside standard AAV and lentiviral programmes. That full continuum—standard excellence plus genuine niche depth—is what distinguishes the service.

Core high-performance gene therapy analytics

AAV, lentiviral, adenoviral, HSV and non-viral product support
Vector and genome identity confirmation
qPCR and ddPCR titre strategy and method development
Physical, infectious and functional titre determination
AAV empty/full ratio and particle distribution analysis
Genome integrity and packaged DNA characterisation
Capsid, envelope and structural protein analytics
Cell-based and molecular potency assay development
Residual host-cell DNA, plasmid DNA, residual proteins and residual nuclease testing
Replication-competent virus (RCV/RCL) testing strategies
Sterility, mycoplasma, endotoxin and adventitious-agent testing
Stability-indicating assay suites
Comparability and process-change analytical support
Method qualification, validation and technology transfer
Spain- and Switzerland-linked analytical execution
Full GMP and GMP-like documentation packages
Rare and emerging vector serotypes or engineered capsids outside standard commercial panels
Complex multi-component non-viral and hybrid delivery systems
Ultra-sensitive residual impurity methods pushed to the lowest quantifiable levels required for high-dose or paediatric programmes
Custom potency formats for novel payloads, dual-expression systems or tissue-specific activity readouts
Advanced particle and structural characterisation beyond routine empty/full (including high-resolution distribution and integrity metrics)
Integrated genome packaging and integrity studies linked directly to process parameters
Replication-competent virus strategies tailored to non-standard vector designs
Comparability packages designed for major process platform changes or manufacturing site transfers
Micro-batch and early-phase analytical support for programmes too small or too specialised for larger platforms
Parallel analytical suites that simultaneously generate release, characterisation and process-understanding data from the same sample set

FAQ: Gene Therapy Analytics CDMO Services

1. What are Gene Therapy Analytics CDMO Services?

Gene therapy analytics services support analytical development, characterisation, release testing, stability, comparability, and documentation for viral vector and advanced genetic medicine products.

2. What gene therapy products can Sophia support?

Sophia supports AAV, lentiviral, adenoviral, HSV, plasmid DNA, genome-editing, ex vivo cell therapy vector, in vivo gene therapy, and other genetic medicine programmes.

3. What is the difference between physical and functional titre?

Physical titre measures genomes or particles. Functional titre measures the ability of the vector to infect or transduce cells and produce a defined biological outcome.

4. Why is AAV empty/full analysis important?

AAV preparations may contain empty, full, partial, or otherwise heterogeneous capsids. Empty/full analysis helps characterise particle composition, dose, process performance, and product consistency.

5. How is gene therapy potency measured?

Potency may be measured through transduction, transgene expression, protein activity, gene editing, cell phenotype, enzyme function, or another assay linked to the product mechanism.

6. What impurities are tested in viral vectors?

Testing may include residual host-cell DNA, plasmid DNA, host-cell proteins, nucleases, transfection reagents, media components, endotoxin, aggregates, empty particles, and product-specific process impurities.

7. What is replication-competent virus testing?

Replication-competent virus testing evaluates whether a nominally replication-defective vector preparation contains virus capable of uncontrolled replication.

8. Can one assay define a gene therapy product?

No. Gene therapy products require orthogonal assays covering identity, quantity, purity, structure, potency, safety, and stability.

9. Can Sophia support method transfer and validation?

Yes. Sophia supports analytical method development, qualification, validation strategy, transfer, bridging, comparability, and lifecycle planning.

10. What should sponsors provide to begin an analytics programme?

Useful starting information includes vector type, capsid or envelope, construct map, manufacturing process, current assays, development stage, target specifications, reference materials, formulation, stability conditions, and known analytical gaps.

Conclusion

Sophia provides gene therapy analytics CDMO services for viral vector, genome-editing, plasmid DNA, and advanced genetic medicine programmes.

The analytical strategy must establish identity, quantity, structural integrity, potency, purity, safety, stability, and batch consistency. No single titre or potency result can define a complex gene therapy product.

Through specialised capabilities in Spain and Switzerland, Sophia supports method development, characterisation, comparability, validation, and GMP/GMP-like documentation from early development through release readiness.

Email our team at info@sophiacdmo.com